FTC’s Stance in Teva-Amneal Case Signals Potential Shift in Orange Book Patent Listings

The U.S. Court of Appeals for the Federal Circuit is poised to hear oral arguments in the case of Teva Branded Pharmaceutical Products R&D v. Amneal Pharmaceuticals of New York, raising significant legal questions surrounding the listing of Teva’s patents in the FDA’s Orange Book. This legal showdown follows the Federal Trade Commission’s unexpected decision to file an amicus brief supporting Amneal Pharmaceuticals’ position on delisting efforts. This move has piqued the curiosity of legal professionals, as they consider the potential implications of the FTC’s involvement on future patent disputes and administrative policies for the Orange Book. The context and analysis of this case may offer insight into upcoming regulatory trends as the new administration approaches.